Immune-checkpoint blockade in cisplatin-ineligible patients with urothelial cancer
Mené sur 123 patients atteints d'un carcinome urothélial de stade métastatique ou localement avancé et inéligibles à un traitement par cisplatine, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité de l'atézolizumab, un anti PD-L1, en traitement de première ligne
The clinical benefit of cisplatin-based chemotherapy is supported by evidence obtained from multiple randomised controlled trials.1–2 Unfortunately, up to two-thirds of patients are ineligible to receive cisplatin-based chemotherapy because of impaired renal function, poor performance status, hearing loss, neuropathy, or heart failure.3 Although intravesical immunotherapy with Bacille Calmette Guerin (BCG) has been a mainstay in the treatment of non-muscle-invasive urothelial carcinoma of the bladder, only in the past year has systemic immunotherapy shown efficacy and safety for patients with advanced urothelial carcinoma, leading to the US Food and Drug Administration's approval of atezolizumab for patients with chemotherapy-refractory disease.
The Lancet , commentaire, 2015